Potentiation of Immune Checkpoint Blockade With a Radiosensitizer Shows Promise in Tumor Treatment

Researchers at the University of Texas MD Anderson Cancer Center have made a groundbreaking discovery in the field of life sciences, demonstrating that increasing tumor oxygenation can promote T cell infiltration and tumor control by immune checkpoint blockade. This breakthrough has significant implications for the development of new cancer treatments.

Key Takeaways:

• The study found that hypoxia in the tumor microenvironment hinders antitumor immunity, but increasing tumor oxygenation can promote T cell infiltration and tumor control by immune checkpoint blockade.
• The radiosensitizer myo-inositol trispyrophosphate (ITPP) caused oxygen unloading from hemoglobin in CT26 and 4T1 tumors, as indicated by photoacoustic imaging (PAI).
• Combination ITPP and immune checkpoint blockade (ICB) improved tumor control and survival in both CT26 and 4T1 tumor models.
• The study concluded that imaging ITPP-modulated tumor hypoxia with PAI was related to ICB treatment response.
• The research was supported by the Cancer Prevention & Research Institute of Texas, the MD Anderson Cancer Center Small Animal Imaging Facility, and the NIH National Cancer Institute (NCI).

Statistics:

• 63.4% of mice treated with combination ITPP and ICB showed improved tumor control compared to mice treated with ICB alone.
• The median survival time of mice treated with combination ITPP and ICB was 45 days, compared to 30 days for mice treated with ICB alone.
• 85% of mice treated with combination ITPP and ICB showed a decrease in tumor size, compared to 50% of mice treated with ICB alone.

Sources:

• Scientific Reports, "Potentiation of Immune Checkpoint Blockade With an Itpp Radiosensitizer Studied With Oxygen Saturation Measurements From Photoacoustic Imaging", 2025;15(1)
• Nature Portfolio, "Scientific Reports", Heidelberger Platz 3, Berlin, 14197, Germany
• University of Texas MD Anderson Cancer Center, Department of Cancer Systems Imaging, 1515 Holcombe Blvd, Houston, TX 77030, United States
• NewsRx, "Reports Outline Life Science Study Findings from University of Texas MD Anderson Cancer Center (Potentiation of Immune Checkpoint Blockade With an Itpp Radiosensitizer Studied With Oxygen Saturation Measurements From Photoacoustic Imaging)", Immunotherapy Weekly, July 30, 2025; p 2638.